BioDelivery hopes modified REMS will put cancer pain drug Onsolis in retail pharmacies
06 June 2011
Nancy Faigen
Please Login to read the full article.
06 June 2011
Nancy Faigen
nancy.faigen@informausa.com
Please Login to read the full article.
RELATED CONTENT
NEWS
- BioDelivery clinches $30M up front from Endo in deal for PhIII buccal mucosa chronic pain treatment
- Pain drug disappoints in Phase III, but BDSI plans new trial
- BDSI CEO: Shared fentanyl REMS puts Onsolis on level playing field
- Stay for BioDelivery in MonoSol thin-film patents dispute
COMMENT
Other Informa Comment
EVENTS
Today
Le Plaza Hotel, Brussels, Belgium
Today
Diplomat Hotel, Prague, Czech Republic
Today
Business Design Centre, London
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
